

Clovis Oncology, Inc.
Form 4
August 29, 2016

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Check this box
if no longer
subject to
Section 16.
Form 4 or
Form 5
obligations
may continue.
See Instruction
1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB
Number: 3235-0287
Expires: January 31,
2005
Estimated average
burden hours per
response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person *
MUEHL DANIEL W

(Last) (First) (Middle)

C/O CLOVIS ONCOLOGY,
INC., 5500 FLATIRON PARKWAY

(Street)

BOULDER, CO 80301

(City) (State) (Zip)

2. Issuer Name **and** Ticker or Trading
Symbol
Clovis Oncology, Inc. [CLVS]

3. Date of Earliest Transaction
(Month/Day/Year)
08/25/2016

4. If Amendment, Date Original
Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to
Issuer

(Check all applicable)

____ Director ____ 10% Owner
__X__ Officer (give title below) ____ Other (specify below)

See Remarks

6. Individual or Joint/Group Filing(Check
Applicable Line)
__X__ Form filed by One Reporting Person
____ Form filed by More than One Reporting
Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
				(A) or (D)			
			Code	V	Amount		Price

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of
information contained in this form are not
required to respond unless the form
displays a currently valid OMB control
number.**

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security	2. Conversion or Exercise	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any	4. Transaction Code	5. Number of Derivative Securities	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)

Edgar Filing: Clovis Oncology, Inc. - Form 4

(Instr. 3)	Price of Derivative Security	(Month/Day/Year)	(Instr. 8)	Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)							
			Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Stock Option (right to buy)	\$ 22.73	08/25/2016	A		37,500		<u>(1)</u>	08/25/2026	Common Stock	37,500	
Restricted Stock Units	<u>(2)</u>	08/25/2016	A		8,750		<u>(3)</u>	<u>(3)</u>	Common Stock	8,750	
Stock Option (right to buy)	\$ 84.83						<u>(4)(5)</u>	07/06/2025	Common Stock	35,000	
Stock Option (right to buy)	\$ 19.37						<u>(4)(5)</u>	03/01/2026	Common Stock	7,500	
Restricted Stock Units	<u>(2)</u>						<u>(6)</u>	<u>(6)(7)</u>	Common Stock	2,500	

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
MUEHL DANIEL W C/O CLOVIS ONCOLOGY, INC. 5500 FLATIRON PARKWAY BOULDER, CO 80301				See Remarks

Signatures

/s/ Daniel W.
Muehl

08/29/2016

**Signature of
Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1)

Edgar Filing: Clovis Oncology, Inc. - Form 4

The option shall vest as to 25% of the shares on August 25, 2017, and the remainder shall vest in substantially equal installments over the 36 months immediately following such date.

- (2) Each restricted stock unit represents the right to receive one share of Common Stock.
- (3) The restricted stock units shall vest as to 25% of the units on August 25, 2017, and the remainder shall vest in substantially equal installments over the 12 quarters immediately following such date.
- (4) The option vested as to 25% of the shares on July 6, 2016, and the remainder vest in substantially equal installments over the 36 months immediately following such date.
- (5) The vesting schedule for this option was incorrectly reported on a previously filed Form 3. This Form 4 reflects the correct vesting schedule.
- (6) The restricted stock units shall vest as to 50% of the units on March 1, 2017, and the remainder shall vest on March 1, 2018.
- (7) An expiration date was incorrectly reported for these restricted stock units on a previously filed Form 3. This Form 4 reflects that the restricted stock units do not have such an expiration date.

Remarks:

Vice President of Finance, Principal Financial Officer and Principal Accounting Officer

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.